Endocyte, Inc. (ECYT)

Oncology Corporate Profile

Stock Performance

4.0800
-0.0300

HQ Location

3000 Kent Avenue, Suite A1-100
West Lafayette, IN 47906

Company Description

Endocyte has developed a novel technology to improve the safety and efficacy of existing drugs by targeting them directly to diseased cells. Endocyte's unique drug guidance system may make treatment of cancer and other diseases more successful by enabling the use of higher doses of more potent drugs with greater efficacy and fewer side effects.

Website: http://www.endocyte.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
vintafolide / EC145chemotherapeutic conjugate (vinca alkaloid)Endometrial cancerII
vintafolide / EC145chemotherapeutic conjugate (vinca alkaloid)Non Small Cell Lung Cancer (NSCLC)II
vintafolide / EC145chemotherapeutic conjugate (vinca alkaloid)Ovarian cancerII
etarfolatide / EC20imaging agentVarious cancer typesII
EC17immunotherapy1st line metastatic Renal cell carcinoma (RCC)I
EC1669TubBH inhibitorProstate cancerI
EC0652imaging agentProstate cancerI
EC0225chemotherapeutic conjugate (vinca alkaloid)Various cancer typesI
EC1456TubBH inhibitorVarious cancer typesI
BMS753493chemotherapeutic conjugate (epothilone)Various cancer typesI
EC0489chemotherapeutic conjugate (microtubule inhibitor)Various cancer typesI
EC178folate-DNA alkylator inhibitorVarious cancer typesPreclinical
EC0531chemotherapeutic conjugateVarious cancer typesPreclinical

View additional information on product candidates here »

Source


http://www.endocyte.com

Recent News Headlines

Researchers Question FDA's Use of Surrogate Endpoints for Cancer Drug Approvals

10/20/2015 11:01 am

(Regulatory Focus) Oct 19, 2015 - Two researchers are questioning the US Food and Drug Administration's (FDA) use of surrogate endpoints in approving new oncology drugs and the agency's failure to more strictly enforce postmarketing study requirements for these drugs, according to a letter appearing in JAMA Internal Medicine.

Study: Two-Thirds Of New Cancer Drugs Not Found To Extend Life

10/20/2015 07:00 am

(Milwaukee Journal Sentinel) Oct 19, 2015 - Two-thirds of new cancer drugs in the past five years were approved not because they extended or improved life but based on so-called surrogate measures of effectiveness, such as scans showing tumor shrinkage, according to a paper published Monday in JAMA Internal Medicine.

Debate Over Early-Stage Cancer: To Treat or Not to Treat?

10/20/2015 07:00 am

(Wall Street Journal) Oct 19, 2015 - With certain early-stage cancers, more researchers favor giving patients the option to forgo surgery and radiation in favor of a less-aggressive option called ‘active surveillance.’

Shire's Dry Eye Drug Hit With US Rejection

10/19/2015 12:04 pm

(PharmaTimes [UK]) Oct 18, 2015 - Shire’s bid to secure US approval for its experimental dry eye disease therapy lifitegrast has hit a bump in the road after regulators issued a complete response letter outlining some additional requests regarding the application following a priority review.

Bluebird Shares Plunge on Waning Effect of Old Gene Therapy

10/19/2015 12:01 pm

(The Street) Oct 19, 2015 - Bluebird Bio shares fell 13% to $74.69 Monday afternoon -- the stock's lowest price this year -- after the company said a patient treated with a first-generation version of its gene therapy suffered a relapse seven years later.

FDA Approves Praxbind, The First Reversal Agent For The Anticoagulant Pradaxa

10/19/2015 12:00 pm

(FDA.gov) Oct 16, 2015 - The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.

J&J's Stelara Succeeds in Phase III Crohn's Disease Trial

10/19/2015 12:00 pm

(Reuters) Oct 19, 2015 - Johnson & Johnson's Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn's disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine.

Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors

10/19/2015 11:03 am

(StreetInsider) Oct 19, 2015 - Curis, Inc. today announced the expansion of its pipeline with the addition of two programs, the first of which is an oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA), and the second is focused on inhibitors of Interleukin-1 receptor-associated kinase 4 (IRAK4).

Results of Hematology/Oncology Pharmacy Association and Eisai Inc. Survey Show 83 Percent of Patients Receiving Chemotherapy May Be Unnecessarily Suffering from Chemotherapy-induced Nausea and Vomiting

10/19/2015 11:03 am

(Eisai) Oct 19, 2015 - Oct. 19, 2015 - Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live.

Sientra Breast Implants Stuck in Limbo After Supplier's Setbacks

10/19/2015 11:03 am

(Bloomberg) Oct 16, 2015 - Sientra Inc. aimed to take on the kings of the breast-implant industry when it entered the U.S. market in 2012, offering women what it said was a new set of shapes and textures to choose from -- round or shaped, smooth or textured, oval or classic.

Federal Court Rules Against HRSA’s 340B Orphan Drug Policy

10/19/2015 11:03 am

(ACCC) Oct 16, 2015 - On Oct. 14, 2015, a federal court struck down a Health Resources and Services Administration (HRSA) 340B orphan drug policy that permitted safety-net hospitals to purchase orphan drugs at discounted prices under certain conditions.

Cancer Drug Helps Parkinson's Patients

10/19/2015 11:03 am

(NBC News) Oct 17, 2015 - A pill usually prescribed to treat leukemia has had dramatic effects in a few patients with Parkinson's disease, doctors reported Saturday.

High-flying Kite Could Score Big With New Cancer Treatment

10/19/2015 11:03 am

(Los Angeles Times) Oct 17, 2015 - Kite Pharma, one of the hottest biotech start-ups on Wall Street, hopes to revolutionize the treatment of a common, deadly lymphatic cancer — with a novel mix of highly trained lab techs and high-speed air travel.

Cambridge Biotech Bids To Become Leading Cancer Drug Maker

10/19/2015 11:03 am

(Boston Globe) Oct 17, 2015 - No one can accuse Merrimack Pharmaceuticals Inc. of doing things the easy way in its transition from a biotech research startup to a commercial company.

Sequenom To Explore The Clinical Utility Of A Novel Liquid Biopsy Assay In Melanoma Patients In Collaboration With University Of Colorado Denver

10/19/2015 11:02 am

(Morningstar) Oct 19, 2015 - Sequenom, Inc. today announced that it has entered into a clinical collaboration with the University of Colorado Denver, School of Medicine (CU School of Medicine).

Big Data, Meet Big Money: NIH Funds Centers to Crunch Health Data

10/10/2014 06:05 am

(Los Angeles Times) Oct 9, 2014 - Calling the world's wealth of health data a formidable "engine of discovery," the National Institutes of Health on Thursday awarded $32 million in grants in a bid to make huge biomedical data sets accessible to researchers the world over.

Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe

5/20/2014 01:05 am

(MarketWatch) May 19, 2014 - Merck and Endocyte, Inc. today announced the withdrawal of conditional marketing authorization applications (CMA) from the European Medicines Agency (EMA) for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous (IV) folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD).

Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis

5/2/2014 02:01 am

(Merck) May 2, 2014 - Merck and Endocyte, Inc. today announced that the Data Safety Monitoring Board (DSMB) of the PROCEED trial recommended that the trial be stopped because vintafolide did not demonstrate efficacy on the pre-specified outcome of Progression-Free Survival (PFS) in patients with platinum-resistant ovarian cancer.

Endocyte Announces DSMB Recommendation for Continuation of Vintafolide/Docetaxel Combination and Docetaxel Monotherapy Arms of the Phase 2b TARGET Trial in Non-Small Cell Lung Cancer

10/11/2013 11:00 am

(MarketWatch) Oct 11, 2013 - Endocyte, Inc. today announced the outcomes of the planned independent Data Safety Monitoring Board (DSMB) review of the interim futility analysis for the Phase 2b TARGET trial with investigational candidate vintafolide (MK-8109/EC145).

ASCO Endorses Legislation Providing Parity to Cancer Drugs

7/25/2013 11:01 am

(ASCO) July 24, 2013 - ASCO has endorsed the Cancer Drug Coverage Parity Act of 2013 (H.R. 1801), bipartisan federal legislation that would require private health insurance plans offering intravenous chemotherapy benefits to provide parity for orally administered and self-injectable anticancer medications.

Breast Cancer Treatment Halts Bone Metastases and Also Protects Bones

3/13/2013 11:02 am

(Medical University of Vienna) Mar 11, 2013 - A team of researchers at the MedUni Vienna, led by Michael Gnant from the University Department of Surgery at the MedUni Vienna, has discovered two further positive effects of the drug Everolimus, which is already being used successfully as a hormone treatment for breast cancer.

Diagnovus Launches First Commercial Gene Expression Assay for Patients With Diffuse Large B-Cell Lymphoma

2/20/2013 11:01 am

(MarketWatch) Feb 20, 2013 - Diagnovus, LLC, a molecular diagnostic company focused on underserved, aggressive and lesser-known diseases, today announced the launch of ENGAUGE(TM)-cancer-DLBCL, the first commercial gene expression assay that can aid physicians in better risk stratification and treatment of patients with diffuse large B-cell lymphoma (DLBCL).

Endocyte to Advance Development of EC1069, a PSMA-Targeted Small Molecule Drug Conjugate Therapy for Prostate Cancer

1/30/2013 12:05 pm

(Yahoo! Finance) Jan 29, 2013 - Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced the achievement of key objectives in a Phase 0 study of EC0652, a diagnostic imaging agent targeting prostate specific membrane antigen (PSMA), a protein expressed on cancer cells originating from the prostate as well as on tumor neovasculature.

Endocyte Secures DOXIL(R) Supply to Support Ongoing Phase 3 PROCEED Trial in Ovarian Cancer

8/2/2012 11:04 am

(Marketwatch) Aug 2, 2012 - Endocyte, Inc., a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company has secured DOXIL(R) (doxorubicin HCl liposome injection) supply from Janssen Products, LP, to supplement existing supply already in place to support the ongoing Phase 3 PROCEED trial in ovarian cancer.

More Than 16 Million People with Medicare Get Free Preventative Services in 2012

7/10/2012 12:01 pm

(CMS) July 10, 2012 - The Affordable Care Act – the new health care law – helped over 16 million people with original Medicare get at least one preventive service at no cost to them during the first six months of 2012, Health and Human Services (HHS) Secretary Kathleen Sebelius announced today.